Literature DB >> 12607212

Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation.

N Müller1, M Riedel, M Ackenheil, M J Schwarz.   

Abstract

Immune alterations in schizophrenia have been described for decades. However, modern immunological methods and new insights into the highly developed and functionally differentiated immune system allow an integrative view of both the older and also more recent findings of immunological abnormalities in schizophrenia. The conceptual advances in immunology require the re-evaluation of elder immunological findings in schizophrenia. In this overview, recent advances in immunological research regarding the differentiation between T-Helper-1 and T-Helper-2 cells and between the so-called specific and unspecific arms of the immune system are discussed. The unspecific "innate" immune system shows signs of an over-activation in unmedicated schizophrenic patients, as increased monocytes and gamma delta-cells point to. Increased levels of Interleukin-6 (IL-6) and the activation of the IL-6 system in schizophrenia might be the result of the activation of monocytes/macrophages, too. In contrast, several parameters of the specific cellular immune system are blunted, e.g. the decreased T-helper-1 (TH-1) related immune parameters in schizophrenic patients, both in vitro and in vivo. It seems that a TH-1-TH-2 imbalance with a shift to the TH-2 system is associated with schizophrenia. During therapy with antipsychotics, the specific TH-1 related immune answer becomes activated, but the B-cell system and the antibody production become activated too.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 12607212     DOI: 10.3109/15622970009150588

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  22 in total

1.  Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features.

Authors:  Clemente Garcia-Rizo; Emilio Fernandez-Egea; Cristina Oliveira; Azucena Justicia; Miguel Bernardo; Brian Kirkpatrick
Journal:  Psychiatry Res       Date:  2012-03-08       Impact factor: 3.222

2.  Impaired monocyte activation in schizophrenia: ultrastructural abnormalities and increased IL-1β production.

Authors:  Natalya A Uranova; P D Bonartsev; L V Androsova; V I Rakhmanova; V G Kaleda
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-03-17       Impact factor: 5.270

3.  Psychotropic effects of antimicrobials and immune modulation by psychotropics: implications for neuroimmune disorders.

Authors:  Demian Obregon; Ellisa Carla Parker-Athill; Jun Tan; Tanya Murphy
Journal:  Neuropsychiatry (London)       Date:  2012-08

Review 4.  [Immunology in schizophrenic disorders].

Authors:  N Müller; M J Schwarz
Journal:  Nervenarzt       Date:  2007-03       Impact factor: 1.214

5.  Immune System and Schizophrenia.

Authors:  Norbert Müller; Markus J Schwarz
Journal:  Curr Immunol Rev       Date:  2010-08

Review 6.  Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.

Authors:  N Muller; M Schwarz
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

Review 7.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

8.  Priming of metabolic dysfunctions by prenatal immune activation in mice: relevance to schizophrenia.

Authors:  Gustavo Pacheco-López; Sandra Giovanoli; Wolfgang Langhans; Urs Meyer
Journal:  Schizophr Bull       Date:  2011-12-19       Impact factor: 9.306

Review 9.  Th17 pathway-mediated immunopathogenesis of schizophrenia: mechanisms and implications.

Authors:  Monojit Debnath; Michael Berk
Journal:  Schizophr Bull       Date:  2014-04-07       Impact factor: 9.306

Review 10.  Markers of vulnerability in schizophrenia.

Authors:  Maria Ladea; Dan Prelipceanu
Journal:  J Med Life       Date:  2009 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.